GHK-Cu Glutathione Recovery Blend (GGH)

How GHK-Cu Glutathione Recovery Blend (GGH) works in the body

Dosing evidence

Dose at a glance

There is no FDA-approved dosing. No FDA-approved GGH fixed-combination product exists, so there is no approved starting dose, maintenance dose, SC dose, IM dose, dosing frequency, cycle length or titration schedule.

Community and vendor dosing

Community protocols describe 0.5 to 1 mL per injection, approximately 2 to 3 times per week, by SC or IM administration. This is a community or vendor protocol example, not clinically validated GGH dosing. The actual dose depends entirely on the concentration of each active ingredient, and no clinically validated GGH dose has been established.

Why mL alone is not enough

A volume does not say how much GHK-Cu, glutathione or any other active ingredient is being given. Compare two hypothetical GGH products:

Taking 1 mL of each would mean completely different active doses. A GGH protocol cannot be interpreted from injection volume alone: the amount of each ingredient per dose, in mg or another appropriate unit, is needed.

Exact formula

Before any GGH dose can be interpreted, the exact formulation of the specific product needs to be known:

• GHK-Cu: mg/mL
• Glutathione: mg/mL
• Histidine: mg/mL, if present
• Glycine: mg/mL, if present
• NADH: mg/mL, if present
• Any other ingredients

Community protocol comparison

The biggest problem: 0.5 to 1 mL cannot be compared across formulations without knowing the mg/mL of each ingredient.

Frequency at a glance

No clinically established frequency exists for GGH. There is no controlled human trial showing that the exact blend should be given daily, every other day, twice a week, three times a week or weekly. Community reports describe use several times per week; this is community practice. Best-supported frequency: unknown.

Timing at a glance

There is no evidence that the GGH blend works better in the morning, at night, fasted, with food, before exercise or after exercise.

Duration and cycling

There is no established clinical GGH cycle; community durations vary. No evidence shows a biological requirement for 5 days on / 2 days off, 8-week cycles, 12-week cycles, 2-week washouts or 4-week washouts.

GGH is not one conventional receptor agonist. It is a blend of compounds with different biological roles, and there is no established GGH receptor, GHK-Cu receptor-reset protocol, glutathione receptor reset or required washout period. Verdict: no evidence-based receptor-reset logic.

Route

Subcutaneous and intramuscular use are both described in community and vendor practice. No controlled GGH clinical program establishes either route. Both are community routes.

Expected results timeline

A clinical timeline is not established. No controlled human GGH study supports a timeline such as better recovery in week 1, brighter skin in week 2, more collagen in week 4 or tissue regeneration in week 8; these are not clinical facts.

Community sources may describe changes in skin appearance, recovery, perceived inflammation and general wellness over days or weeks. These remain anecdotal observations and are separate from clinical study timelines for the individual ingredients.

Protocol logic check

Copper exposure

GHK-Cu contains copper, so total copper exposure is potentially relevant. The risk cannot be evaluated from 0.5 mL or 1 mL unless the amount of GHK-Cu in that volume is known. Estimating copper exposure requires the GHK-Cu concentration, the amount injected, the exact molecular form and the frequency. Copper exposure cannot be quantified from an mL-only protocol.

Can the ingredients be assumed to be synergistic?

No. GHK-Cu and glutathione have different biological roles, which can make the combination sound complementary, but different mechanisms do not equal clinical synergy. No controlled human study was identified showing that the exact combination produces better outcomes than either component alone. Verdict: mechanistically interesting, clinically unproven.

Medical literature and study context

What is GGH?

GGH is a community or vendor blend name, not one standardized drug or molecule. It is usually described as a blend of GHK-Cu and glutathione. Some products sold as GGH also contain other ingredients such as histidine, glycine or NADH, so the name alone does not say exactly what is in the vial. The ingredient list is formula-dependent.

Community GGH products are generally marketed around recovery, skin, antioxidant support, tissue repair and general regeneration. These are community and vendor research goals, not established indications for the finished blend.

Name warning: GGH is not Gly-Gly-His

In scientific literature, GGH can also mean Gly-Gly-His (glycyl-glycyl-histidine), a separate copper-binding tripeptide. It is not the commercial GGH blend discussed here, and studies of the Gly-Gly-His peptide are not evidence for GHK-Cu and glutathione GGH blends.

What does GHK-Cu do?

GHK is a naturally occurring tripeptide (Gly-His-Lys) that can bind copper to form GHK-Cu. GHK-Cu has been studied for effects involving the extracellular matrix, collagen, tissue remodeling, wound biology, inflammatory signaling and oxidative stress. It appears to act more like a tissue-signaling and remodeling molecule than a conventional drug acting through one receptor. This is GHK-Cu evidence, not GGH blend evidence.

Some human GHK-Cu evidence exists, but much of the better human evidence relates to topical use rather than long-term injection protocols.

What does glutathione do?

Glutathione is one of the body's most important naturally occurring antioxidants, and its biological role is extremely well established. It takes part in cellular redox balance, antioxidant defense, detoxification chemistry and protection against oxidative stress. Being biologically essential does not show that injecting extra glutathione in a GGH blend improves health in an otherwise healthy person, or that it improves recovery, skin quality, energy, healing, liver function or aging.

Some research involves glutathione and skin pigmentation, but the evidence differs considerably between oral, topical and IV use, and research on one route does not transfer to another.

GHK-Cu and glutathione compatibility

Laboratory research has shown that glutathione can chemically interact with Cu(II)-GHK. The chemistry involves reduction of the copper center and formation of intermediate copper-thiolate species. The two ingredients are therefore not necessarily chemically invisible to each other when mixed.

This does not prove that every GGH vial is unstable, that every blend degrades rapidly, that the mixture is unsafe or that all biological activity is lost. It means same-vial compatibility and stability need to be demonstrated for the exact product rather than assumed. Verdict: formulation-specific compatibility data needed.

What may it help with?

GHK-Cu component: biological evidence supports research into extracellular matrix remodeling, collagen-related processes, skin repair, wound biology, tissue regeneration and inflammatory signaling. That does not mean an injectable GGH blend produces the same results.

Glutathione component: strong biological roles in antioxidant defense, cellular redox balance and protection from oxidative stress.

What has the exact blend been proven to help with?

No specific clinical benefit has been established. The exact blend has not been proven to:

• accelerate wound healing
• improve skin quality
• increase collagen
• lighten skin
• improve athletic recovery
• repair muscles
• repair tendons
• detoxify the liver
• reduce inflammation clinically
• improve mitochondrial function
• increase energy
• slow aging

The ingredients may give biological reasons to study some of these areas. That is different from showing the finished blend works clinically.

What studies have found

GHK-Cu research supports biological roles in tissue remodeling, the extracellular matrix, collagen, wound biology, inflammation and oxidative stress. It supports GHK-Cu as a biologically active compound; it does not support a specific GGH injection protocol.

Glutathione research shows glutathione is essential to normal redox biology, with human research on supplementation, oxidative stress and pigmentation. It does not show that injecting glutathione as part of GGH is a proven recovery or anti-aging treatment.

GHK-Cu and glutathione chemistry: laboratory research directly demonstrates interaction between Cu(II)-GHK and glutathione. The ingredients can chemically affect each other. This does not show that every finished formulation rapidly degrades, is ineffective or is unsafe; compatibility must be demonstrated, not assumed.

Independent evidence

Three evidence categories

1. GHK-Cu research. Legitimate research on skin, collagen, wound healing and tissue remodeling, though much of the stronger human evidence is topical rather than injectable.

2. Glutathione research. Strong biological evidence and separate human research, with evidence that differs between oral, topical, IV and other injection routes.

3. GGH blend evidence. The weakest category. The finished combination has not been shown to inherit every proven or proposed benefit of its individual ingredients. Component evidence is not combination evidence.

Research at a glance

Exact GGH blend

Evidence strength

Overall rating: strong component biology, very weak exact-blend evidence.

Regulatory status

There is no FDA-approved GGH product, and no approved fixed-combination product was identified. FDA has specifically raised safety concerns about injectable compounded GHK-Cu. Glutathione has separate compounding and sterile-product considerations. The regulatory status of a component does not determine the status of the finished blend.

FDA's compounding framework treats GHK-Cu by non-injectable routes differently from injectable GHK-Cu, because injectable formulations raise additional concerns involving sterility, aggregation, impurities and immunogenicity. GHK-Cu is not FDA approved, and it is also inaccurate to say all GHK-Cu is banned.

Bottom line

GGH is a poorly standardized blend name used in the research and community market, built from ingredients that individually have legitimate biological research. That does not make the blend clinically validated. GGH is not one standardized compound; different GGH products may contain different ingredients; dose cannot be interpreted from mL alone; no validated human GGH dosing protocol has been identified; component evidence does not prove combination efficacy; GHK-Cu and glutathione can chemically interact; injectable GHK-Cu has specific FDA safety concerns; and injectable glutathione carries important sterile-product quality risks. The exact formula and concentration need to be known before any GGH protocol can be meaningfully evaluated.

Storage

No standardized GGH formulation exists

There is no approved product defining one universal ingredient list, ingredient ratio, concentration, diluent, pH, reconstitution method, storage temperature or post-reconstitution expiration.

Same-vial stability

Because GHK-Cu and glutathione can chemically interact, same-vial stability cannot be assumed. Stability of a given formulation may depend on pH, excipients, ingredient ratios, oxygen exposure, temperature, storage time and copper oxidation state. Exact formulation data are required.

Generic 14-day and 28-day rules

There is no universal evidence that every GGH vial remains chemically stable, sterile and potent for 14 or 28 days after reconstitution. Stability information applies only to the exact formulation and product it was generated for.

Contraindications & cautions

Formal contraindications

None are established, because no approved GGH product or label exists.

FDA injectable GHK-Cu safety concerns

FDA has specifically identified injectable GHK-Cu as raising potential immunogenicity concerns related to peptide aggregation and peptide-related impurities, and notes that human safety information for injectable GHK-Cu is limited. This does not mean GHK-Cu injections are proven dangerous; it means the injectable route has unresolved product-quality and immune-response concerns.

Injectable glutathione product-quality risk

FDA has documented serious adverse events after improperly prepared compounded injectable glutathione. Reported symptoms included nausea, vomiting, lightheadedness, chills and body aches. One person developed low blood pressure and difficulty breathing and required hospital transfer. FDA testing found excessive bacterial endotoxin in the glutathione material involved.

These reactions reflect poor sterile-product quality from improperly sourced glutathione, not the normal pharmacology of glutathione itself. Product quality is a separate safety issue.

Important cautions

• Copper metabolism disorders / Wilson disease: GHK-Cu contains copper, and people with disorders of copper handling may need particular caution. Important biological and clinical caution, not a formal GGH contraindication.
• Pregnancy and breastfeeding: safety of the exact blend is not established.
• Concurrent copper-altering therapy: could affect interpretation of copper exposure. Clinical caution.
• Active malignancy: tissue-remodeling, angiogenesis and wound-healing biology is too complex to make active cancer an established contraindication. Uncertain, theoretical caution only.

Possible side effects

Long-term safety of the exact GGH blend is unknown. No robust clinical safety program was identified for the exact formulation.

Endotoxin reactions from contaminated injectable glutathione are a product-quality risk, covered under cautions, not a normal glutathione side effect.

Compatibility

Commonly paired with

Within the vial itself, GHK-Cu and glutathione can chemically interact, so same-vial compatibility must be demonstrated for the exact formulation.

Sources

1. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (injectable GHK-Cu: immunogenicity, aggregation, peptide-related impurities, limited human safety information). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
2. U.S. Food and Drug Administration. 503A Bulk Drug Substances update (regulatory distinctions for GHK-Cu, injectable GHK-Cu and glutathione).
3. U.S. Food and Drug Administration. FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables (endotoxin contamination and associated adverse events). https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables
4. Ufnalska et al. Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione. 2021. https://pubmed.ncbi.nlm.nih.gov/34781677/
5. Pickart et al. Regenerative and Protective Actions of the GHK-Cu Peptide. https://pubmed.ncbi.nlm.nih.gov/29986520/
6. GHK-Cu / GHK anti-aging review (biological and mechanistic review). https://pubmed.ncbi.nlm.nih.gov/35083444/
7. PeptideDosingProtocols. GHK-Cu (community practice; topical versus injectable evidence). https://www.peptidedosingprotocols.com/protocol/ghk-cu
8. PeptideDosages. GHK-Cu 100 mg vial dosage protocol (standalone GHK-Cu community dose examples; not evidence for the GGH blend). https://peptidedosages.com/single-peptide-dosages/ghk-cu-100-mg-vial-dosage-protocol/
9. Glutathione skin-lightening systematic review (oral, topical and IV glutathione evidence). https://pubmed.ncbi.nlm.nih.gov/39444151/
10. PeptidePlotter. GGH (vendor blend documentation listing GHK-Cu, glutathione, histidine, glycine and NADH; not clinical efficacy evidence). https://peptideplotter.com/compounds/ggh